Breaking Science Session at the 2025 American Academy of Neurology (AAN) meeting, Remegen announced exciting results from a ...

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

J&J exhibited additional findings, displaying that nipocalimab met its key secondary endpoint, a change in QMG score.

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...

The trial included 238 patients, with 80% AChR+ and 20% MuSK+, and demonstrated low rates of serious adverse events. Ongoing analyses are assessing additional endpoints like MG exacerbations ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction ...

anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADL b and QMG scores from the ongoing open-label extension (OLE) of the ...